FiercePharma

Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

- Praluent will be available in both a 75 mg and 150 mg dose for self-administration every two weeks - Paris and Tarrytown, New York - September 28, 2015 - Sanofi and Regeneron Pharmaceuticals, Inc.
FiercePharma

Regeneron and Sanofi Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection for Preferred Access

TARRYTOWN, N.Y. and BRIDGEWATER, N.J, Dec. 11, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that UnitedHealth Group will provide preferred access to Praluent ...
TCTMD

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

TARRYTOWN, N.Y. and PARIS, Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent ® (alirocumab) Injection met its ...
Pharmabiz

US FDA approves Praluent injection to treat high LDL cholesterol

Sanofi, an integrated global healthcare leader, and Regeneron Pharmaceuticals, Inc., a leading science-based biopharmaceutical company, announced that the US Food and Drug Administration (FDA) ...